1978 W Winton Ave
Be part of pandemic-speed manufacturing for medicines
Talent is, and will always be, at the heart of our business. As part of our long-term growth strategy, we plan for significant expansion in Hayward, CA over the next 3 years. We are looking for talent to join us in various positions such as Quality Assurance, Operations, Regulatory, Engineering, Program Management, and many more.
We are one of the world's leading and most trusted suppliers to the pharmaceutical and biotech markets. We continue to break new ground within our industry, attracting global clients to our Hayward site. Rooted in the Bay Area and close to innovation in vaccines and therapeutics, we provide state-of-the-art, single-use manufacturing technology to support our customers with their clinical programs and through to commercial launch. Whether our customers are developing life-saving therapies for cancer or potential treatments for COVID-19, we can support them with world class manufacturing and process excellence.
With a history that dates back to 1897, Lonza is a trusted name with a wealth of knowledge and expertise in life science. Today we are more than 15,000 employees in more than 100 locations around the world. Together in 2019, we supported the development and production of over 1000 therapies.
We offer you exposure to upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the potential blockbuster treatments of tomorrow. While other companies may only offer you the opportunity to work on a few treatments, at Lonza you will be working on scores of treatments per year for a variety of customers.
We are here to make a meaningful difference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming it. What we do today is helping to create a healthier, happier world tomorrow. That’s the meaningful difference we make every day.
215 articles with Lonza
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities
MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany a leading science and technology company, announced the acquisition of MAST® platform from Lonza.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It's been a busy week so far, with new discovery facilities launched in the biotech space.
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
Triumvira's T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza's Cocoon ® platform at the C3i Center Inc (C3i) in Montreal
New Lonza Webinar – “An Automated Integrated QC Laboratory – MODA-EM® Software & Growth Direct® System”
On 21 September, Lonza will host a free 30-minute webinar to discuss how quality control (QC) laboratories can maximize efficiency for reduced costs and time-to-results by combining Lonza’s MODA-EM® Software and the Growth Direct® System from Rapid Micro Biosystems.
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has entered into an additional agreement with Lonza to support drug substance manufacturing for its global supply chain.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
Lonza has been in the process of separating LSI into a standalone unit since 2019.
The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO of Arbor: “Arbor's differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics. Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development and manufacturing of biological and cellular therapies.”
Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network
Be The Match BioTherapies as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy (CGT) supply chain support
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
In an effort to change the course of this pandemic, advancing lead COVID-19 therapeutics requires matched supply chain efforts and expertise to meet the continued and urgent patient needs.
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
- Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platform - IsoLight® to be used for functional quality analytics for cell therapy products produced on Lonza's Cocoon® Platform, an automated cell manufacturing platform [20-August-2020] BASEL, Switzerland and BRANFORD, Conn. , Aug. 20, 2020 /PRNewswire/ -- Quote from Matthew Hewitt , Hea
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine against the novel coronavirus and additional Moderna products in the future.
As the situation progresses, they hope to establish more production suites across Lonza’s facilities globally, with a goal of manufacturing up to 1 billion doses of mRNA-1273 per year at the currently expected dose of 50 µg.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat kidney disease announces that it has granted the manufacturing contract for the active pharmaceutical ingredient for XRx-101 and XRx-008 to Lonza Pharma & Biotech.
Free Lonza webinar to discuss the benefits of using physiologically relevant 3D cell culture models to enhance respiratory research for diseases like COVID-19
Lonza Launches New TheraPEAK™ SfAAV™ Medium to Boost and Optimize the Production of AAV in Sf9 Insect Cells
Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells